{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:30:56Z","timestamp":1791199856450,"version":"4.2.0"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP25fk0210123"],"award-info":[{"award-number":["JP25fk0210123"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP25fk0310535"],"award-info":[{"award-number":["JP25fk0310535"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP25fk0210174"],"award-info":[{"award-number":["JP25fk0210174"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP25fk0210125"],"award-info":[{"award-number":["JP25fk0210125"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["23HC2001"],"award-info":[{"award-number":["23HC2001"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["23HC2003"],"award-info":[{"award-number":["23HC2003"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["23HC2002"],"award-info":[{"award-number":["23HC2002"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Radiol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s11604-025-01930-2","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T05:10:03Z","timestamp":1769490603000},"page":"465-475","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Metabolic dysfunction-associated steatotic liver disease (MASLD): definition, diagnosis, natural history, and treatment"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4634-6616","authenticated-orcid":false,"given":"Nobuharu","family":"Tamaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takefumi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun-Ichi","family":"Wakabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoo","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanobu","family":"Iwadare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7016-8931","authenticated-orcid":false,"given":"Masayuki","family":"Kurosaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"1930_CR1","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/nrgastro.2013.171","volume":"10","author":"R Loomba","year":"2013","unstructured":"Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10:686\u201390.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1930_CR2","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/s41575-024-00967-4","volume":"21","author":"LY Mak","year":"2024","unstructured":"Mak LY, Liu K, Chirapongsathorn S, et al. Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions. Nat Rev Gastroenterol Hepatol. 2024;21:834\u201351.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1930_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2023.155744","volume":"152","author":"DJH Tan","year":"2024","unstructured":"Tan DJH, Ng CH, Muthiah M, et al. Rising global burden of cancer attributable to high BMI from 2010 to 2019. Metabolism. 2024;152:155744.","journal-title":"Metabolism"},{"key":"1930_CR4","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966\u201386.","journal-title":"Hepatology"},{"key":"1930_CR5","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79:1542\u201356.","journal-title":"J Hepatol"},{"key":"1930_CR6","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/S2468-1253(24)00193-6","volume":"9","author":"H Hagstr\u00f6m","year":"2024","unstructured":"Hagstr\u00f6m H, Shang Y, Hegmar H, et al. Natural history and progression of metabolic dysfunction-associated steatotic liver disease. Lancet Gastroenterol Hepatol. 2024;9:944\u201356.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1930_CR7","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/apt.16745","volume":"55","author":"M Higuchi","year":"2022","unstructured":"Higuchi M, Tamaki N, Kurosaki M, et al. Longitudinal association of magnetic resonance elastography-associated liver stiffness with complications and mortality. Aliment Pharmacol Ther. 2022;55:292\u2013301.","journal-title":"Aliment Pharmacol Ther"},{"key":"1930_CR8","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.cgh.2021.07.021","volume":"20","author":"N Tamaki","year":"2022","unstructured":"Tamaki N, Higuchi M, Kurosaki M, et al. Risk difference of liver-related and cardiovascular events by liver fibrosis status in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2022;20:1171-1173.e2.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1930_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23063107","author":"T Androutsakos","year":"2022","unstructured":"Androutsakos T, Nasiri-Ansari N, Bakasis AD, et al. SGLT-2 inhibitors in NAFLD: expanding their role beyond diabetes and cardioprotection. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23063107.","journal-title":"Int J Mol Sci"},{"key":"1930_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24021703","author":"R Nevola","year":"2023","unstructured":"Nevola R, Epifani R, Imbriani S, et al. GLP-1 receptor agonists in non-alcoholic fatty liver disease: current evidence and future perspectives. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24021703.","journal-title":"Int J Mol Sci"},{"key":"1930_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100261","volume":"3","author":"OT Ayonrinde","year":"2021","unstructured":"Ayonrinde OT. Historical narrative from fatty liver in the nineteenth century to contemporary NAFLD\u2014reconciling the present with the past. JHEP Rep. 2021;3:100261.","journal-title":"JHEP Rep"},{"key":"1930_CR12","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/S0025-6196(24)00530-5","volume":"55","author":"J Ludwig","year":"1980","unstructured":"Ludwig J, Viggiano TR, McGill DB, et al. Nonalcoholic steatohepatitis: mayo clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434\u20138.","journal-title":"Mayo Clin Proc"},{"key":"1930_CR13","first-page":"283","volume":"8","author":"F Schaffner","year":"1986","unstructured":"Schaffner F, Thaler H. Nonalcoholic fatty liver disease. Prog Liver Dis. 1986;8:283\u201398.","journal-title":"Prog Liver Dis"},{"key":"1930_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11\u201320.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1930_CR15","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1111\/liv.16093","volume":"44","author":"T Tada","year":"2024","unstructured":"Tada T, Kurosaki M, Toyoda H, et al. Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection who had received direct-acting antiviral therapy. Liver Int. 2024;44:3060\u201371.","journal-title":"Liver Int"},{"key":"1930_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.13068","volume":"8","author":"A Morita","year":"2024","unstructured":"Morita A, Tamaki N, Kobashi H, et al. Effect of treatment periods on efficacy of glecaprevir and pibrentasvir in chronic hepatitis C: a nationwide, prospective, multicenter study. JGH Open. 2024;8:e13068.","journal-title":"JGH Open"},{"key":"1930_CR17","doi-asserted-by":"publisher","first-page":"6247","DOI":"10.1002\/jmv.27157","volume":"93","author":"T Tada","year":"2021","unstructured":"Tada T, Kurosaki M, Nakamura S, et al. Real-world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1- and 2-infected patients with decompensated cirrhosis: a nationwide multicenter study by the Japanese Red Cross Liver Study Group. J Med Virol. 2021;93:6247\u201356.","journal-title":"J Med Virol"},{"key":"1930_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.14025","volume":"32","author":"T Iwadare","year":"2025","unstructured":"Iwadare T, Kimura T, Sugiura A, et al. Thrombospondin 2 as a predictive biomarker for HCC in hepatitis C patients: a longitudinal study following DAA therapy. J Viral Hepat. 2025;32:e14025.","journal-title":"J Viral Hepat"},{"key":"1930_CR19","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1111\/hepr.14047","volume":"54","author":"H Enomoto","year":"2024","unstructured":"Enomoto H, Akuta N, Hikita H, et al. Etiological changes of liver cirrhosis and hepatocellular carcinoma-complicated liver cirrhosis in Japan: updated nationwide survey from 2018 to 2021. Hepatol Res. 2024;54:763\u201372.","journal-title":"Hepatol Res"},{"key":"1930_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.08.021","volume":"80","author":"L Chen","year":"2024","unstructured":"Chen L, Tao X, Zeng M, et al. Clinical and histological features under different nomenclatures of fatty liver disease: NAFLD, MAFLD, MASLD and MetALD. J Hepatol. 2024;80:e64-e66.","journal-title":"J Hepatol"},{"key":"1930_CR21","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1016\/j.jhep.2023.07.017","volume":"80","author":"V Ratziu","year":"2024","unstructured":"Ratziu V, Boursier J. Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD. J Hepatol. 2024;80:e51\u20132.","journal-title":"J Hepatol"},{"key":"1930_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.08.026","volume":"80","author":"H Hagstr\u00f6m","year":"2024","unstructured":"Hagstr\u00f6m H, Vessby J, Ekstedt M, et al. 99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical. J Hepatol. 2024;80:e76\u2013e77.","journal-title":"J Hepatol"},{"key":"1930_CR23","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/hepr.14011","volume":"54","author":"K Suzuki","year":"2024","unstructured":"Suzuki K, Tamaki N, Kurosaki M, et al. Concordance between metabolic dysfunction-associated steatotic liver disease and nonalcoholic fatty liver disease. Hepatol Res. 2024;54:600\u20135.","journal-title":"Hepatol Res"},{"key":"1930_CR24","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41574-021-00584-0","volume":"18","author":"N Tamaki","year":"2022","unstructured":"Tamaki N, Ajmera V, Loomba R. Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD. Nat Rev Endocrinol. 2022;18:55\u201366.","journal-title":"Nat Rev Endocrinol"},{"key":"1930_CR25","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/hep.24452","volume":"54","author":"R Hernaez","year":"2011","unstructured":"Hernaez R, Lazo M, Bonekamp S, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology. 2011;54:1082\u201390.","journal-title":"Hepatology"},{"key":"1930_CR26","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1111\/hepr.13179","volume":"48","author":"N Tamaki","year":"2018","unstructured":"Tamaki N, Koizumi Y, Hirooka M, et al. Novel quantitative assessment system of liver steatosis using a newly developed attenuation measurement method. Hepatol Res. 2018;48:821\u20138.","journal-title":"Hepatol Res"},{"key":"1930_CR27","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1136\/gutjnl-2021-324264","volume":"71","author":"N Tamaki","year":"2022","unstructured":"Tamaki N, Munaganuru N, Jung J, et al. Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease. Gut. 2022;71:983\u201390.","journal-title":"Gut"},{"key":"1930_CR28","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","volume":"184","author":"R Loomba","year":"2021","unstructured":"Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021;184:2537\u201364.","journal-title":"Cell"},{"key":"1930_CR29","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1016\/j.cgh.2024.06.026","volume":"22","author":"RW Zeng","year":"2024","unstructured":"Zeng RW, Ong CEY, Ong EYH, et al. Global prevalence, clinical characteristics, surveillance, treatment allocation, and outcomes of alcohol-associated hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2024;22:2394\u20132402.e15.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1930_CR30","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","volume":"18","author":"DQ Huang","year":"2021","unstructured":"Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021;18:223\u201338.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1930_CR31","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/apt.18015","volume":"60","author":"N Tamaki","year":"2024","unstructured":"Tamaki N, Kimura T, Wakabayashi SI, et al. Long-term clinical outcomes in steatotic liver disease and incidence of liver-related events, cardiovascular events and all-cause mortality. Aliment Pharmacol Ther. 2024;60:61\u20139.","journal-title":"Aliment Pharmacol Ther"},{"key":"1930_CR32","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2025.1809","author":"P Ochoa-Allemant","year":"2025","unstructured":"Ochoa-Allemant P, Hubbard RA, Kaplan DE, et al. Adverse liver outcomes, cardiovascular events, and mortality in steatotic liver disease. JAMA Intern Med. 2025. https:\/\/doi.org\/10.1001\/jamainternmed.2025.1809.","journal-title":"JAMA Intern Med"},{"key":"1930_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2025.04.027","author":"DH Kim","year":"2025","unstructured":"Kim DH, Ko D, Danpanichkul P, et al. Longitudinal clinical outcomes and mortality from steatotic liver disease: a meta-analysis. Am J Med. 2025. https:\/\/doi.org\/10.1016\/j.amjmed.2025.04.027.","journal-title":"Am J Med"},{"key":"1930_CR34","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/s41575-023-00818-8","volume":"20","author":"DQ Huang","year":"2023","unstructured":"Huang DQ, Singal AG, Kanwal F, et al. Hepatocellular carcinoma surveillance\u2014utilization, barriers and the impact of changing aetiology. Nat Rev Gastroenterol Hepatol. 2023;20:797\u2013809.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1930_CR35","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","volume":"69","author":"G Targher","year":"2020","unstructured":"Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut. 2020;69:1691\u2013705.","journal-title":"Gut"},{"key":"1930_CR36","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1136\/gutjnl-2020-322786","volume":"70","author":"TG Simon","year":"2021","unstructured":"Simon TG, Roelstraete B, Khalili H, et al. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. Gut. 2021;70:1375\u201382.","journal-title":"Gut"},{"key":"1930_CR37","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1136\/gutjnl-2023-331003","volume":"73","author":"HH Lee","year":"2024","unstructured":"Lee HH, Lee HA, Kim EJ, et al. Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease. Gut. 2024;73:533\u201340.","journal-title":"Gut"},{"key":"1930_CR38","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1111\/apt.18205","volume":"60","author":"N Tamaki","year":"2024","unstructured":"Tamaki N, Kimura T, Wakabayashi SI, et al. Cardiometabolic criteria as predictors and treatment targets of liver-related events and cardiovascular events in metabolic dysfunction-associated steatotic liver disease. Aliment Pharmacol Ther. 2024;60:1033\u201341.","journal-title":"Aliment Pharmacol Ther"},{"key":"1930_CR39","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","volume":"73","author":"G Targher","year":"2024","unstructured":"Targher G, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut. 2024;73:691\u2013702.","journal-title":"Gut"},{"key":"1930_CR40","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.cgh.2023.09.018","volume":"22","author":"KE Chan","year":"2024","unstructured":"Chan KE, Ong EYH, Chung CH, et al. Longitudinal outcomes associated with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of 129 studies. Clin Gastroenterol Hepatol. 2024;22:488\u2013498.e14.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1930_CR41","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/bjc.2014.579","volume":"112","author":"V Bagnardi","year":"2015","unstructured":"Bagnardi V, Rota M, Botteri E, et al. Alcohol consumption and site-specific cancer risk: a comprehensive dose-response meta-analysis. Br J Cancer. 2015;112:580\u201393.","journal-title":"Br J Cancer"},{"key":"1930_CR42","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.3748\/wjg.v24.i13.1440","volume":"24","author":"T Kimura","year":"2018","unstructured":"Kimura T, Tanaka N, Fujimori N, et al. Mild drinking habit is a risk factor for hepatocarcinogenesis in non-alcoholic fatty liver disease with advanced fibrosis. World J Gastroenterol. 2018;24:1440\u201350.","journal-title":"World J Gastroenterol"},{"key":"1930_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.12.018","author":"T Kimura","year":"2025","unstructured":"Kimura T, Tamaki N, Wakabayashi SI, et al. Colorectal cancer incidence in steatotic liver disease (MASLD, MetALD, and ALD). Clin Gastroenterol Hepatol. 2025. https:\/\/doi.org\/10.1016\/j.cgh.2024.12.018.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1930_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.05.013","author":"P Ochoa-Allemant","year":"2025","unstructured":"Ochoa-Allemant P, Hubbard RA, Kaplan DE, et al. Cause-specific mortality in patients with steatotic liver disease in the United States. J Hepatol. 2025. https:\/\/doi.org\/10.1016\/j.jhep.2025.05.013.","journal-title":"J Hepatol"},{"key":"1930_CR45","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","volume":"385","author":"AJ Sanyal","year":"2021","unstructured":"Sanyal AJ, Van Natta ML, Clark J, et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med. 2021;385:1559\u201369.","journal-title":"N Engl J Med"},{"key":"1930_CR46","doi-asserted-by":"publisher","first-page":"30","DOI":"10.14309\/ajg.0000000000002572","volume":"119","author":"LL Jophlin","year":"2024","unstructured":"Jophlin LL, Singal AK, Bataller R, et al. ACG clinical guideline: alcohol-associated liver disease. Am J Gastroenterol. 2024;119:30\u201354.","journal-title":"Am J Gastroenterol"},{"key":"1930_CR47","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s12072-021-10143-4","volume":"15","author":"T Ito","year":"2021","unstructured":"Ito T, Ishigami M, Zou B, et al. The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with individual and forecasting analysis, 1995\u20132040. Hepatol Int. 2021;15:366\u201379.","journal-title":"Hepatol Int"},{"key":"1930_CR48","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1002\/hep.32774","volume":"77","author":"TC Yip","year":"2023","unstructured":"Yip TC, Vilar-Gomez E, Petta S, et al. Geographical similarity and differences in the burden and genetic predisposition of NAFLD. Hepatology. 2023;77:1404\u201327.","journal-title":"Hepatology"},{"key":"1930_CR49","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/HEP.0000000000000329","volume":"78","author":"O Nabi","year":"2023","unstructured":"Nabi O, Lapidus N, Boursier J, et al. Lean individuals with NAFLD have more severe liver disease and poorer clinical outcomes (NASH-CO Study). Hepatology. 2023;78:272\u201383.","journal-title":"Hepatology"},{"key":"1930_CR50","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3350\/cmh.2024.0631","volume":"31","author":"P Danpanichkul","year":"2025","unstructured":"Danpanichkul P, Suparan K, Prasitsumrit V, et al. Long-term outcomes and risk modifiers of metabolic dysfunction-associated steatotic liver disease between lean and non-lean populations. Clin Mol Hepatol. 2025;31:74\u201389.","journal-title":"Clin Mol Hepatol"},{"key":"1930_CR51","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1007\/s00535-024-02093-z","volume":"59","author":"SI Wakabayashi","year":"2024","unstructured":"Wakabayashi SI, Tamaki N, Kimura T, et al. Natural history of lean and non-lean metabolic dysfunction-associated steatotic liver disease. J Gastroenterol. 2024;59:494\u2013503.","journal-title":"J Gastroenterol"},{"key":"1930_CR52","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1007\/s12072-024-10716-z","volume":"18","author":"M Souza","year":"2024","unstructured":"Souza M, Diaz I, Al-Sharif L. Liver and cardiovascular outcomes in lean non-alcoholic fatty liver disease: an updated systematic review and meta-analysis of about 1 million individuals. Hepatol Int. 2024;18:1396\u2013415.","journal-title":"Hepatol Int"},{"key":"1930_CR53","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1016\/j.cgh.2022.11.019","volume":"21","author":"J Ha","year":"2023","unstructured":"Ha J, Yim SY, Karagozian R. Mortality and liver-related events in lean versus non-lean nonalcoholic fatty liver disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2023;21:2496\u20132507.e5.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1930_CR54","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s12876-023-02848-7","volume":"23","author":"S Ishido","year":"2023","unstructured":"Ishido S, Tamaki N, Takahashi Y, et al. Risk of cardiovascular disease in lean patients with nonalcoholic fatty liver disease. BMC Gastroenterol. 2023;23:211.","journal-title":"BMC Gastroenterol"},{"key":"1930_CR55","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1111\/hepr.13911","volume":"53","author":"M Kawanaka","year":"2023","unstructured":"Kawanaka M, Nishino K, Kawada M, et al. Lean nonalcoholic fatty liver disease: age-dependent differences in pathology, prognosis, and liver-related events. Hepatol Res. 2023;53:829\u201343.","journal-title":"Hepatol Res"},{"key":"1930_CR56","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1080\/00365520802588133","volume":"44","author":"K Yasutake","year":"2009","unstructured":"Yasutake K, Nakamuta M, Shima Y, et al. Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease: the significance of dietary cholesterol. Scand J Gastroenterol. 2009;44:471\u20137.","journal-title":"Scand J Gastroenterol"},{"key":"1930_CR57","doi-asserted-by":"publisher","DOI":"10.3390\/nu15040891","author":"M Iwaki","year":"2023","unstructured":"Iwaki M, Kobayashi T, Nogami A, et al. Impact of sarcopenia on non-alcoholic fatty liver disease. Nutrients. 2023. https:\/\/doi.org\/10.3390\/nu15040891.","journal-title":"Nutrients"},{"key":"1930_CR58","doi-asserted-by":"publisher","first-page":"10186","DOI":"10.1038\/s41598-020-67147-7","volume":"10","author":"H Takada","year":"2020","unstructured":"Takada H, Amemiya F, Yasumura T, et al. Relationship between presarcopenia and event occurrence in patients with primary hepatocellular carcinoma. Sci Rep. 2020;10:10186.","journal-title":"Sci Rep"},{"key":"1930_CR59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0309852","volume":"20","author":"H Takada","year":"2025","unstructured":"Takada H, Osawa L, Komiyama Y, et al. Serum interferon-gamma-induced protein 10 levels can help predict sarcopenia development in patients with primary hepatocellular carcinoma: a retrospective cohort study. PLoS ONE. 2025;20:e0309852.","journal-title":"PLoS ONE"},{"key":"1930_CR60","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1002\/hep.32047","volume":"74","author":"S Vilarinho","year":"2021","unstructured":"Vilarinho S, Ajmera V, Zheng M, et al. Emerging role of genomic analysis in clinical evaluation of lean individuals with NAFLD. Hepatology. 2021;74:2241\u201350.","journal-title":"Hepatology"},{"key":"1930_CR61","doi-asserted-by":"publisher","DOI":"10.1172\/JCI162513","author":"N Tamaki","year":"2022","unstructured":"Tamaki N, Ahlholm N, Luukkonen PK, et al. Risk of advanced fibrosis in first-degree relatives of patients with nonalcoholic fatty liver disease. J Clin Invest. 2022. https:\/\/doi.org\/10.1172\/JCI162513.","journal-title":"J Clin Invest"},{"key":"1930_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154455","volume":"115","author":"DA Koutoukidis","year":"2021","unstructured":"Koutoukidis DA, Koshiaris C, Henry JA, et al. The effect of the magnitude of weight loss on non-alcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism. 2021;115:154455.","journal-title":"Metabolism"},{"key":"1930_CR63","doi-asserted-by":"publisher","unstructured":"Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. 2015. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. https:\/\/doi.org\/10.1053\/j.gastro.2015.04.005.","DOI":"10.1053\/j.gastro.2015.04.005"},{"key":"1930_CR64","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/j.1872-034X.2010.00724.x","volume":"40","author":"M Iwasa","year":"2010","unstructured":"Iwasa M, Hara N, Iwata K, et al. Restriction of calorie and iron intake results in reduction of visceral fat and serum alanine aminotransferase and ferritin levels in patients with chronic liver disease. Hepatol Res. 2010;40:1188\u201394.","journal-title":"Hepatol Res"},{"key":"1930_CR65","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/hepr.13764","volume":"52","author":"N Tamaki","year":"2022","unstructured":"Tamaki N, Kurosaki M, Huang DQ, et al. Noninvasive assessment of liver fibrosis and its clinical significance in nonalcoholic fatty liver disease. Hepatol Res. 2022;52:497\u2013507.","journal-title":"Hepatol Res"},{"key":"1930_CR66","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/hep.29085","volume":"65","author":"PS Dulai","year":"2017","unstructured":"Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017;65:1557\u201365.","journal-title":"Hepatology"},{"key":"1930_CR67","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1053\/j.gastro.2021.10.051","volume":"162","author":"R Loomba","year":"2022","unstructured":"Loomba R, Ratziu V, Harrison SA. Expert panel review to compare FDA and EMA guidance on drug development and endpoints in nonalcoholic steatohepatitis. Gastroenterology. 2022;162:680\u20138.","journal-title":"Gastroenterology"},{"key":"1930_CR68","unstructured":"European Association for the Study of the Liver, European Association for the Study of Diabetes. 2024. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 81:492\u2013542."},{"key":"1930_CR69","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77:1797\u2013835.","journal-title":"Hepatology"},{"key":"1930_CR70","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s00535-021-01796-x","volume":"56","author":"K Tokushige","year":"2021","unstructured":"Tokushige K, Ikejima K, Ono M, et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis 2020. J Gastroenterol. 2021;56:951\u201363.","journal-title":"J Gastroenterol"},{"key":"1930_CR71","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1016\/j.clnu.2022.06.037","volume":"41","author":"L Haigh","year":"2022","unstructured":"Haigh L, Kirk C, El Gendy K, et al. The effectiveness and acceptability of Mediterranean diet and calorie restriction in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis. Clin Nutr. 2022;41:1913\u201331.","journal-title":"Clin Nutr"},{"key":"1930_CR72","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0263931","volume":"17","author":"T Fern\u00e1ndez","year":"2022","unstructured":"Fern\u00e1ndez T, Vi\u00f1uela M, Vidal C, et al. Lifestyle changes in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. PLoS ONE. 2022;17:e0263931.","journal-title":"PLoS ONE"},{"key":"1930_CR73","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1002\/hep.30076","volume":"68","author":"C Properzi","year":"2018","unstructured":"Properzi C, O\u2019Sullivan TA, Sherriff JL, et al. Ad libitum Mediterranean and low-fat diets both significantly reduce hepatic steatosis: a randomized controlled trial. Hepatology. 2018;68:1741\u201354.","journal-title":"Hepatology"},{"key":"1930_CR74","doi-asserted-by":"publisher","DOI":"10.3390\/nu15051175","author":"Y Matsumoto","year":"2023","unstructured":"Matsumoto Y, Fujii H, Harima M, et al. Severity of liver fibrosis is associated with the Japanese diet pattern and skeletal muscle mass in patients with nonalcoholic fatty liver disease. Nutrients. 2023. https:\/\/doi.org\/10.3390\/nu15051175.","journal-title":"Nutrients"},{"key":"1930_CR75","doi-asserted-by":"publisher","DOI":"10.3390\/nu16172877","author":"T Sasada","year":"2024","unstructured":"Sasada T, Iino C, Sato S, et al. The impact of Japanese dietary patterns on metabolic dysfunction-associated steatotic liver disease and liver fibrosis. Nutrients. 2024. https:\/\/doi.org\/10.3390\/nu16172877.","journal-title":"Nutrients"},{"key":"1930_CR76","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/hep.32274","volume":"76","author":"JG Stine","year":"2022","unstructured":"Stine JG, Schreibman IR, Faust AJ, et al. NASHFit: a randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH. Hepatology. 2022;76:172\u201385.","journal-title":"Hepatology"},{"key":"1930_CR77","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1136\/gut.2011.242073","volume":"60","author":"K Hallsworth","year":"2011","unstructured":"Hallsworth K, Fattakhova G, Hollingsworth KG, et al. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut. 2011;60:1278\u201383.","journal-title":"Gut"},{"key":"1930_CR78","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1111\/apt.15989","volume":"52","author":"P O'Gorman","year":"2020","unstructured":"O\u2019Gorman P, Naimimohasses S, Monaghan A, et al. Improvement in histological endpoints of MAFLD following a 12-week aerobic exercise intervention. Aliment Pharmacol Ther. 2020;52:1387\u201398.","journal-title":"Aliment Pharmacol Ther"},{"key":"1930_CR79","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.14309\/ajg.0000000000002098","volume":"118","author":"JG Stine","year":"2023","unstructured":"Stine JG, DiJoseph K, Pattison Z, et al. Exercise training is associated with treatment response in liver fat content by magnetic resonance imaging independent of clinically significant body weight loss in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Am J Gastroenterol. 2023;118:1204\u201313.","journal-title":"Am J Gastroenterol"},{"key":"1930_CR80","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.cgh.2021.12.043","volume":"21","author":"HS Chun","year":"2023","unstructured":"Chun HS, Lee M, Lee HA, et al. Association of physical activity with risk of liver fibrosis, sarcopenia, and cardiovascular disease in Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2023;21:358\u2013369.e12.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1930_CR81","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1016\/j.cgh.2021.01.023","volume":"20","author":"MH Malespin","year":"2022","unstructured":"Malespin MH, Barritt ASt, Watkins SE, et al. Weight loss and weight regain in usual clinical practice: results from the TARGET-NASH observational cohort. Clin Gastroenterol Hepatol. 2022;20:2393\u20132395.e4.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1930_CR82","doi-asserted-by":"publisher","first-page":"632","DOI":"10.21037\/hbsn-23-393","volume":"13","author":"L Luo","year":"2024","unstructured":"Luo L, Ye J, Zhuo S, et al. Specific metabolic impairments indicate loss of sustained liver improvements in metabolic dysfunction-associated steatotic liver disease treatment. Hepatobiliary Surg Nutr. 2024;13:632\u201349.","journal-title":"Hepatobiliary Surg Nutr"},{"key":"1930_CR83","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/j.jhep.2018.08.011","volume":"69","author":"VW Wong","year":"2018","unstructured":"Wong VW, Wong GL, Chan RS, et al. Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease. J Hepatol. 2018;69:1349\u201356.","journal-title":"J Hepatol"},{"key":"1930_CR84","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390:497\u2013509.","journal-title":"N Engl J Med"},{"key":"1930_CR85","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3748\/wjg.v25.i2.163","volume":"25","author":"N Tanaka","year":"2019","unstructured":"Tanaka N, Kimura T, Fujimori N, et al. Current status, problems, and perspectives of non-alcoholic fatty liver disease research. World J Gastroenterol. 2019;25:163\u201377.","journal-title":"World J Gastroenterol"},{"key":"1930_CR86","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/hepr.14025","volume":"54","author":"N Tamaki","year":"2024","unstructured":"Tamaki N, Wakabayashi SI, Kimura T, et al. Glycemic control target for liver and cardiovascular events risk in metabolic dysfunction-associated steatotic liver disease. Hepatol Res. 2024;54:753\u201362.","journal-title":"Hepatol Res"},{"key":"1930_CR87","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S2468-1253(23)00157-7","volume":"8","author":"DQ Huang","year":"2023","unstructured":"Huang DQ, Noureddin N, Ajmera V, et al. Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis. Lancet Gastroenterol Hepatol. 2023;8:829\u201336.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1930_CR88","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.2337\/dci24-0003","volume":"47","author":"DJ Drucker","year":"2024","unstructured":"Drucker DJ. Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity. Diabetes Care. 2024;47:1873\u201388.","journal-title":"Diabetes Care"},{"key":"1930_CR89","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025;392:2089\u201399.","journal-title":"N Engl J Med"},{"key":"1930_CR90","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","volume":"398","author":"E Brown","year":"2021","unstructured":"Brown E, Heerspink HJL, Cuthbertson DJ, et al. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet. 2021;398:262\u201376.","journal-title":"Lancet"},{"key":"1930_CR91","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMoa2410819","volume":"392","author":"AM Jastreboff","year":"2025","unstructured":"Jastreboff AM, le Roux CW, Stefanski A, et al. Tirzepatide for obesity treatment and diabetes prevention. N Engl J Med. 2025;392:958\u201371.","journal-title":"N Engl J Med"},{"key":"1930_CR92","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","volume":"391","author":"R Loomba","year":"2024","unstructured":"Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024;391:299\u2013310.","journal-title":"N Engl J Med"},{"key":"1930_CR93","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa2401755","volume":"391","author":"AJ Sanyal","year":"2024","unstructured":"Sanyal AJ, Bedossa P, Fraessdorf M, et al. A phase 2 randomized trial of survodutide in MASH and fibrosis. N Engl J Med. 2024;391:311\u20139.","journal-title":"N Engl J Med"},{"key":"1930_CR94","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.2337\/dc21-2049","volume":"45","author":"Y Takeshita","year":"2022","unstructured":"Takeshita Y, Honda M, Harada K, et al. Comparison of tofogliflozin and glimepiride effects on nonalcoholic fatty liver disease in participants with type 2 diabetes: a randomized, 48-week, open-label, active-controlled trial. Diabetes Care. 2022;45:2064\u201375.","journal-title":"Diabetes Care"},{"key":"1930_CR95","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/hep4.1696","volume":"6","author":"H Takahashi","year":"2022","unstructured":"Takahashi H, Kessoku T, Kawanaka M, et al. Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD. Hepatol Commun. 2022;6:120\u201332.","journal-title":"Hepatol Commun"},{"key":"1930_CR96","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1097\/HEP.0000000000000855","volume":"80","author":"KS Cheung","year":"2024","unstructured":"Cheung KS, Ng HY, Hui RWH, et al. Effects of empagliflozin on liver fat in patients with metabolic dysfunction-associated steatotic liver disease without diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Hepatology. 2024;80:916\u201327.","journal-title":"Hepatology"},{"key":"1930_CR97","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1001\/jamainternmed.2023.8029","volume":"184","author":"H Jang","year":"2024","unstructured":"Jang H, Kim Y, Lee DH, et al. Outcomes of various classes of oral antidiabetic drugs on nonalcoholic fatty liver disease. JAMA Intern Med. 2024;184:375\u201383.","journal-title":"JAMA Intern Med"},{"key":"1930_CR98","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1007\/s40618-023-02246-6","volume":"47","author":"Y Suzuki","year":"2024","unstructured":"Suzuki Y, Kaneko H, Okada A, et al. Comparison of SGLT2 inhibitors vs. DPP4 inhibitors for patients with metabolic dysfunction associated fatty liver disease and diabetes mellitus. J Endocrinol Invest. 2024;47:1261\u201370.","journal-title":"J Endocrinol Invest"},{"key":"1930_CR99","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-083735","volume":"389","author":"J Lin","year":"2025","unstructured":"Lin J, Huang Y, Xu B, et al. Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial. BMJ. 2025;389:e083735.","journal-title":"BMJ"},{"key":"1930_CR100","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.2015.15629","volume":"316","author":"R Chou","year":"2016","unstructured":"Chou R, Dana T, Blazina I, et al. Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the US preventive services task force. JAMA. 2016;316:2008\u201324.","journal-title":"JAMA"},{"key":"1930_CR101","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/bcp.14943","volume":"88","author":"D Pastori","year":"2022","unstructured":"Pastori D, Pani A, Di Rocco A, et al. Statin liver safety in non-alcoholic fatty liver disease: a systematic review and metanalysis. Br J Clin Pharmacol. 2022;88:441\u201351.","journal-title":"Br J Clin Pharmacol"},{"key":"1930_CR102","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1097\/MJT.0000000000001499","volume":"30","author":"W Dai","year":"2023","unstructured":"Dai W, Xu B, Li P, et al. Statins for the treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: a systematic review and meta-analysis. Am J Ther. 2023;30:e17\u201325.","journal-title":"Am J Ther"},{"key":"1930_CR103","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1016\/S0140-6736(10)61272-X","volume":"376","author":"VG Athyros","year":"2010","unstructured":"Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study: a post-hoc analysis. Lancet. 2010;376:1916\u201322.","journal-title":"Lancet"},{"key":"1930_CR104","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jacl.2017.10.006","volume":"12","author":"S Ishibashi","year":"2018","unstructured":"Ishibashi S, Arai H, Yokote K, et al. Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor \u03b1 modulator, in patients with dyslipidemia: results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. J Clin Lipidol. 2018;12:173\u201384.","journal-title":"J Clin Lipidol"},{"key":"1930_CR105","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1111\/apt.16596","volume":"54","author":"A Nakajima","year":"2021","unstructured":"Nakajima A, Eguchi Y, Yoneda M, et al. Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor \u03b1 modulator (SPPARM\u03b1), versus placebo in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2021;54:1263\u201377.","journal-title":"Aliment Pharmacol Ther"},{"key":"1930_CR106","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1329294","volume":"15","author":"T Iwadare","year":"2024","unstructured":"Iwadare T, Kimura T, Kunimoto H, et al. Long-term pemafibrate treatment exhibits limited impact on body fat mass in patients with hypertriglyceridemia accompanying NAFLD. Front Endocrinol. 2024;15:1329294.","journal-title":"Front Endocrinol"},{"key":"1930_CR107","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10112806","author":"T Iwadare","year":"2022","unstructured":"Iwadare T, Kimura T, Kunimoto H, et al. Higher responsiveness for women, high transaminase levels, and fat percentage to pemafibrate treatment for NAFLD. Biomedicines. 2022. https:\/\/doi.org\/10.3390\/biomedicines10112806.","journal-title":"Biomedicines"},{"key":"1930_CR108","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.2169\/internalmedicine.2248-23","volume":"63","author":"M Yamada-Shimizu","year":"2024","unstructured":"Yamada-Shimizu M, Tamaki N, Kurosaki M, et al. A comparison of alanine aminotransferase normalization between pemafibrate and bezafibrate in patients with nonalcoholic fatty liver disease. Intern Med. 2024;63:1185\u201390.","journal-title":"Intern Med"},{"key":"1930_CR109","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/jgh.16154","volume":"38","author":"Y Suzuki","year":"2023","unstructured":"Suzuki Y, Maekawa S, Yamashita K, et al. Effect of a combination of pemafibrate and a mild low-carbohydrate diet on obese and non-obese patients with metabolic-associated fatty liver disease. J Gastroenterol Hepatol. 2023;38:921\u20139.","journal-title":"J Gastroenterol Hepatol"}],"container-title":["Japanese Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-025-01930-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11604-025-01930-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-025-01930-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T11:02:46Z","timestamp":1772190166000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11604-025-01930-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":109,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1930"],"URL":"https:\/\/doi.org\/10.1007\/s11604-025-01930-2","relation":{},"ISSN":["1867-1071","1867-108X"],"issn-type":[{"value":"1867-1071","type":"print"},{"value":"1867-108X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"assertion":[{"value":"1 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nobuharu Tamaki received a lecture fee from Kowa company. The other authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}